Furthermore, we validated clinically observed JAK1 missense variants in CRC-9 tumor organoids using individual gRNAs, as shown by altered sensitivity to IFN-γ in three-dimensional growth assays, with LOF missense mutations at JAK1 residues 108, 590, and 775 conferring resistance (Figure S7D). This evidence concerns the gene JAK1 and neoplasm.